Federal Updates:
HELP Copays Act: S. 1375, a companion bill to H.R. 830, was introduced April 28 in the U.S. Senate by Sens. Marshall (R-KS), Kaine (D-VA), Murkowski (R-AK), Markey (D-MA), and Ernst (R-IA…
By donating, you are extending critical support to the community affected by inheritable blood disorders, regardless of the amount you contribute. Your donation enables the foundation to undertake essential initiatives such as researching better…
Replaces: 277INTRODUCTION Successful gene therapy will require broad-based, multi-stakeholder participation to define patient eligibility, educate health care providers, educate persons with hemophilia (PWH) and families, and…
Novo Nordisk has notified the National Hemophilia Foundation that they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for their investigational, subcutaneous therapy concizumab.
Concizumab …
Between 2013-2017, the “My Life Our Future” (MLOF) project offered eligible individuals with hemophilia free genotyping, which is historically hard to access, expensive, and not covered by insurance. Conducted through the laboratory analysis of a…
In July 2020 Ferring Pharmaceuticals suspended manufacturing of the nasal spray STIMATE®, a popular product used to treat certain bleeding disorders. The suspension, and subsequent pharmacy level recall, were in response to a packaging seal…
NHF’s Medical and Scientific Advisory Council (MASAC) recently issued four new documents, which are now available for easy access.Document 275 emphasizes the pivotal part physical therapy plays in the integrated…